9+ hour, 8+ min ago  (493+ words) A Phase 1b clinical trial of Eli Lilly's gene therapy VERVE-102 has shown up to 62% reduction in LDL cholesterol with a single dose, raising hopes for long-term treatment of hypercholesterolaemia and heart disease risk. A one-time gene therapy for treating hypercholesterolaemia…...

20+ hour, 15+ min ago  (483+ words) A single infusion of VERVE-102 sharply lowered PCSK9 and LDL cholesterol in a small phase 1 trial, offering early evidence for a potentially durable genetic approach to cholesterol control, while long-term safety and clinical benefit remain to be proven. Study: In Vivo…...

16+ hour, 27+ min ago  (63+ words) Whalesbook Eli Lilly's gene-editing therapy VERVE-102 has shown impressive early results, cutting LDL-C by 62% and PCSK9 protein by 88% in a Phase 1b trial. This one-time treatment, acquired from Verve Therapeutics, aims to offer a permanent solution for high cholesterol patients, reducing the…...

20+ hour, 53+ min ago  (279+ words) In an early-stage clinical trial, published in "The New England Journal of Medicine" and presented at the European Atherosclerosis Society Congress this week, researchers reported that a single infusion of a gene-editing therapy called VERVE-102 sharply lowered LDL cholesterol by…...

17+ hour, 5+ min ago  (275+ words) News Karnataka " 2012 - 2025 As modern health trends continue to evolve, an increasing number of Christians in the United States are embracing what is being called the "biblical diet" " a lifestyle inspired by food principles mentioned in the Bible. The diet focuses…...

23+ hour, 8+ min ago  (195+ words) Inducible nitric oxide synthase (i NOS) is a key enzyme involved in inflammation and immune system activation. Its induction by pro-inflammatory cytokines is understood to contribute to the development of PAH. Studies indicate that i NOS is often overexpressed in…...

1+ day, 5+ min ago  (476+ words) Professor Stephen Nicholls, Director of the Victorian Heart Hospital and Victorian Heart Institute, and Professor of Cardiology at Monash University, is Principal Investigator of a first-in-human trial that could significantly change how we manage cardiovascular risk in the future. The…...

1+ day, 2+ min ago  (481+ words) Professor Stephen Nicholls, Director of the Victorian Heart Hospital and Victorian Heart Institute, and Professor of Cardiology at Monash University, is Principal Investigator of a first-in-human trial that could significantly change how we manage cardiovascular risk in the future. The…...

1+ day, 19+ hour ago  (492+ words) Esperion Therapeutics presented new data at the 2026 European Atherosclerosis Society Congress showing bempedoic acid effectively lowers LDL cholesterol in children aged 6-17 with familial hypercholesterolemia and is well tolerated. A secondary analysis from the CLEAR Outcomes study also identified factors like…...

1+ day, 9+ hour ago  (346+ words) - New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment - Case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride levels throughout the term…...